CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 56 target
Drug / intervention
Olaparibdrug
Likely dose
Not stated in record
Key inclusion· 12
  • ✓Confirmed diagnosis of malignant mesothelioma
  • ✓Age 18 or older
  • ✓BAP1 loss OR mutation disrupting protein function in at least one gene
  • ✓Prior treatment with cisplatin or carboplatin required
Key exclusion· 19
  • ✕Uncontrollable illness that physician deems undesirable
  • ✕Other malignancy unless treatment-free for ≥3 years (except non-melanoma skin cancer, in situ cervical cancer, DCIS, or Stage 1 grade 1 endometrial carcinoma)
  • ✕Platinum-resistant disease (progression during or within 3 months of platinum therapy)
  • ✕Uncontrolled cardiac conditions or congenital long QT syndrome on ECG

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04515836
NCT04515836Phase 2RecruitingOn TrackUpdated 13mo ago
Long Recruiting
CompareCT.gov

Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma

University of Chicago·interventional·Posted Aug 17, 2020·Updated May 6, 2025

In Brief

A Phase 2 clinical trial evaluating Olaparib for Mesothelioma and Homologous Recombination Deficiency. Currently recruiting, targeting 56 participants across 1 site.

Detailed Summary

In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMesothelioma, Homologous Recombination Deficiency
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 2Recruiting
20212022202320242025202620272028
First PostedAug 17, 2020
Enrollment StartFeb 19, 2021
Primary CompletionApr 15, 2028
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 5.9 years agoPrimary completion in 1.8 years

Interventions

Olaparibdrug

Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.